NCT04668521 (OVA360) is a clinical trial of OVA360 in Adnexal Mass, sponsored by Aspira Women's Health.

Who is sponsoring NCT04668521?

NCT04668521 is sponsored by Aspira Women's Health.

What drugs are being tested in NCT04668521?

Interventions in NCT04668521: OVA360.

What condition does NCT04668521 study?

NCT04668521 studies Adnexal Mass, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Hereditary Breast and Ovarian Cancer.

Is NCT04668521 still recruiting?

NCT04668521 is currently terminated. Last updated 26 December 2023.

Last reviewed 2023-12-26 · How we verify

NCT04668521: OVA360

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

Terminated Last updated 26 December 2023

What this trial tests

trial testing OVA360 in Adnexal Mass in 215 participants. Terminated before completion.

Timeline

4 May 2020

Primary endpoint
15 December 2023

15 December 2023

Quick facts

Lead sponsor	Aspira Women's Health
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	215
Start date	4 May 2020
Primary completion	15 December 2023
Estimated completion	15 December 2023
Sites	1 location across United States

Drugs / interventions tested

OVA360

Conditions studied

Adnexal Mass — all drugs for Adnexal Mass →
Germline BRCA1 Gene Mutation — all drugs for Germline BRCA1 Gene Mutation →
Germline BRCA2 Gene Mutation — all drugs for Germline BRCA2 Gene Mutation →
Hereditary Breast and Ovarian Cancer — all drugs for Hereditary Breast and Ovarian Cancer →

Sponsor

Aspira Women's Health

Who can join

18 and older, female only, with Adnexal Mass or Germline BRCA1 Gene Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Adnexal Mass

Currently open trials in the same condition.

NCT06693596 — Masses in Young Patients - International Ovarian Tumour Analysis (MY-IOTA) · recruiting
NCT05761275 — Assessment of Women's Sexual Quality of Life After Benign Adnexal Surgery Using vNOTES Approach · NA · recruiting
NCT05051722 — Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer · recruiting

Other Aspira Women's Health trials

Trials by the same sponsor.

NCT05245695 — Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck) · recruiting
NCT04487405 — A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04668521 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aspira Women's Health
Last refreshed: 26 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04668521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing